LONDON – The EMA published the conclusions of a first attempt to bring its pan-European assessments of absolute efficacy into line with the needs of national health technology assessment (HTA) bodies that are responsible for making judgements on relative efficacy of drugs, to feed into reimbursement decisions at a member state level.